US approval for Endo's 'crush-proof' Opana

The US FDA has approved a new, harder-to-abuse formulation of Endo Pharmaceuticals' extended-release oxymorphone drug Opana ER, pushing the company's share price up by nearly 6% to closing at $36.04, compared with $34.01 at the previous close.